Vir Biotechnology, Inc. (VIR) |
|
23.67 -0.51 (-2.11%)
|
03-17 16:00 |
|
Open: |
24.11 |
Pre. Close: |
24.18 |
|
High:
|
24.38 |
Low:
|
23.42 |
|
Volume:
|
3,119,720 |
Market Cap:
|
3,161(M) |
|
|
|
Technical analysis |
as of: 2023-03-20 7:50:43 AM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 30.88 One year: 34.07 |
| Support: |
Support1: 22.02 Support2: 18.32 |
| Resistance: |
Resistance1: 26.43 Resistance2: 29.17 |
| Pivot: |
23.03  |
| Moving Average: |
MA(5): 23.48 MA(20): 23.7 
MA(100): 25.85 MA(250): 24.79 |
| MACD: |
MACD(12,26): -0.9 Signal(9): -1.1 |
| Stochastic oscillator: |
%K(14,3): 61.5 %D(3): 43.1 |
| RSI: |
RSI(14): 44.3 |
| 52-week: |
High: 31.78 Low: 18.04 |
| Average Vol(K): |
3-Month: 992 (K) 10-Days: 1,421 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ VIR ] has closed below upper band by 15.9%. Bollinger Bands are 60.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
24.44 - 24.56 |
24.56 - 24.65 |
|
Low:
|
23.09 - 23.25 |
23.25 - 23.38 |
|
Close:
|
23.44 - 23.69 |
23.69 - 23.89 |
|
Company Description |
|
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California. |
Headline News |
Tue, 14 Mar 2023
1,062,036 Shares of Vir Biotechnology, Inc. are Purchased by ... - Best Stocks
Mon, 13 Mar 2023
SVB fall casts shadow on early-stage U.S. biotech - Reuters
Fri, 10 Mar 2023
Vir Biotechnology Becomes Oversold (VIR) - Nasdaq
Fri, 10 Mar 2023
Ensign Peak Advisors Inc Grows Stock Holdings in Vir ... - MarketBeat
Thu, 02 Mar 2023
Axa S.A. makes a $550,000 investment in Vir Biotechnology, Inc ... - Best Stocks
Tue, 28 Feb 2023
VIR BIOTECHNOLOGY, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K) - Marketscreener.com
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
134 (M) |
| Shares Float |
85 (M) |
|
% Held by Insiders
|
13.5 (%) |
|
% Held by Institutions
|
74 (%) |
|
Shares Short
|
4,870 (K) |
|
Shares Short P.Month
|
4,040 (K) |
Stock Financials |
|
EPS
|
4.01 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
15.6 |
|
Profit Margin (%)
|
31.9 |
|
Operating Margin (%)
|
56.2 |
|
Return on Assets (ttm)
|
23.9 |
|
Return on Equity (ttm)
|
29.3 |
|
Qtrly Rev. Growth
|
-94 |
|
Gross Profit (p.s.)
|
10.63 |
|
Sales Per Share
|
12.13 |
|
EBITDA (p.s.)
|
6.86 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
1,660 (M) |
|
Levered Free Cash Flow
|
1,520 (M) |
Stock Valuations |
|
PE Ratio
|
5.88 |
|
PEG Ratio
|
-1 |
|
Price to Book value
|
1.51 |
|
Price to Sales
|
1.95 |
|
Price to Cash Flow
|
1.9 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
